|
|
|
| Effect of Benbromarone Combined with Low-Dose Febuxostat on Scd163 and NLRP3 Levels in Patients with Hyperuricemia and Gout |
| ZHOU Bowei |
| General Hospital of Shanxi Taiyuan Iron and Steel Group Co. Ltd, Shanxi Taiyuan 030008, China |
|
|
|
|
Abstract Objective: To observe the effect of benbromarone combined with low-dose febuxostat on soluble monocyte macrophage hemoglobin scavenger receptor (sCD163) and nucleotide binding oligomerization domain like receptor 3 (NLRP3) in patients with hyperuricemia (HUA) and gout. Methods: 110 patients with HUA and gout in our hospital from September 2017 to December 2020 were selected, and they were randomly divided into control group (55 cases) and study group (55 cases). Patients in the control group were treated with benbromarone, while patients in the study group were treated with benbromarone combined with low-dose febuxostat for 2 months. The clinical total effective rate, serum sCD163, NLRP3 levels and renal function indexes of the two groups were observed after treatment, and the occurrence of adverse reactions in the two groups were recorded. Results: The clinical total effective rate of the study group was higher than that of the control group, the difference was statistically significant (P<0.05). After treatment, the level of sCD163 in the observation group was higher than that in the control group, and the levels of NLRP3, Serum creatinine (Scr), uric acid (BUA), blood urea nitrogen (BUN) in the observation group were lower than those in the control group, the difference was statistically significant (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion: Benbromaton combined with low dose of fenbustam in the treatment of patients with gout can promote BUA excretion, effectively regulate the serum levels of scd163 and NLRP3, promote the recovery of renal function, and the effect is significant.
|
|
|
|
|
|
[1] Vargas-Santos AB,Neogi T.Management of gout and hyperuricemia in CKD[J].Am Kidney Dis,2017,70(3):422~439.
[2] Chen J,Wu M,Yang J,et al.The immunological basis in the pathogenesis of gout[J].Iran Immunol,2017,14(2):90~98.
[3] 查艺军,何剑.郑州地区高尿酸血症流行病学研究[J].临床研究,2021,29(6):10~12.
[4] Hosoya T,Sano T,Sasaki T,et al.Dotinurad versus benzbromarone in Japanese hyperuricemic patient with or without gout:a randomized,double-blind,parallel-group,phase 3 study[J].Clin Exp Nephrol,2020,24(Suppl 1):62~70.
[5] White WB,Saag KG,Becker MA,et al.Cardiovascular safety of febuxostat or allopurinol in patients with gout[J].N Engl Med,2018,378(13):1200~1210.
[6] 中华医学会内分泌学分会.高尿酸血症和痛风治疗的中国专家共识 [J].中华内分泌代谢杂志,2013,29(11):913~920.
[7] 杨颜瑜,柳涛红,王聃,等.间歇期痛风患者中性粒细胞/淋巴细胞比值的变化及其临床意义研究[J].中国全科医学,2021,24(14):1820~1827.
[8] 满达夫,侯云霞,李鸿斌.尿酸对急性发作期痛风患者外周血中性粒细胞胞外诱捕网形成的影响及其临床意义[J].山西医科大学学报,2021,52(3):356~363.
[9] 钟毅,陈泽娜,张萍萍,等.AS合并高尿酸血症患者血清sCD163水平的研究[J].新医学,2016,47(3):150~152.
[10] 周凤婷,姜兰斌,黄萍.狼疮性肾炎患者血清sCD163、sCD134的表达及与疾病活动度的相关性研究[J].河北医药,2019,41(24):3734~3737.
[11] 迟坤,付章宁,宋成成,等.高尿酸通过TXNIP/NLRP3通路导致内皮细胞焦亡[J].中华肾病研究电子杂志,2021,10(2):81~89.
[12] Hosoya T,Sano T,Sasaki T,et al.Dotinurad versus benzbromarone in Japanese hyperuricemic patient with or without gout:a randomized,double-blind,parallel-group,phase 3 study[J].Clin Exp Nephrol,2020,24(Suppl 1):62~70.
[13] Mackenzie IS,Ford I,Nuki G,et al.Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST):a multicentre,prospective,randomised,open-label,non-inferiority trial[J].Lancet,2020,396(10264):1745~1757.
[14] 万红梅.苯溴马隆片联合非布司他在高尿酸血症治疗中的临床研究[J].医药论坛杂志,2021,42(5):114~117. |
|
|
|
2021, Vol. 27 
